FY2025 Q1 Financial Briefing Material

August 6, 2025 JMDC Inc.

2

FY2025 Q1: Performance Highlights

The core Healthcare-Big Data segment continues to drive growth and maintain high growth.

Consolidated Revenue

(Million JPY)

Healthcare-Big Data Revenue

Y-o-Y

Transaction volume by data utilization area

For Industry

+50％

Y-o-Y

For Payers For Medical and Individuals Service Providers

+32％

+27％ +35％

Consolidated EBITDA

(Million JPY)

Y-o-Y

+38％

Healthcare-Big Data EBITDA

Y-o-Y

Pep Up related sales

Y-o-Y

+33％

Number of Pep Up IDs

7.52 million people

3

Note: IFRS-based

EBITDA: Operating profit + Depreciation and amortization costs ± Other profits and/or losses

FY2025 Q1: Management Viewpoints

In order to further deepen the understanding of shareholders, investors and other stakeholders, we will provide management viewpoints.

Management Viewpoints

• The Healthcare-Big Data segment performed well, enabling us to get off to a good start overall. Business expanded in a well-balanced manner in the areas for Industry, for Payers/Individuals, and for Medical Service Providers, and we believe that stable business growth is being achieved.

  In particular, the business for Industry grew strongly, partly due to the fact that some sales that had been expected to be recorded in Q2 were recorded in Q1.On the other hand, even excluding this effect, the underlying business foundation is growing strongly.

• Profit performance also remained steady. Our business has a sales bias toward H2, so Q1 is typically a quarter with limited profit growth due to the impact of increased fixed costs associated with business expansion. However, in Q1 of the current fiscal year, in addition to significant revenue growth, growth investments are coming to an end, resulting in significant profit growth..

  What are the factors contributing to the recovery of the business for Industry?

• The most significant factor is the continued steady expansion of growth areas such as pharmaceutical marketing and consulting. The utilization of elderly data accumulated in advance during the previous fiscal year is still in the proposal stage in Q1, but even without including the results of this, Q1 performance was strong, which is positive. In addition, customer response to proposals for elderly data has been favorable, and data assets for business expansion are steadily increasing, which is expected to contribute to further business growth in the future.

• Regarding business for life insurance companies, preparations for large-scale projects are progressing, and the business has started off largely as expected.

  How do you view the performance outlook for FY2025 Q2?

• We expect business to remain steady in Q2. Although revenue and profits that were recorded in advance in Q1 will be deducted from Q2, even taking this into account, based on the current business situation, we expect strong growth momentum for H1 as a whole.

  In particular, the Healthcare-Big Data segment is expected to make steady progress, with the progress rate in Q2 at 46% of the annual target for revenue and 37% for EBITDA, which is a solid level compared to the past (FY2024: 43% for revenue and 36% for EBITDA; FY2023: 38% for revenue and 31% for EBITDA).

  How is the progress of social implementation of data?

• In addition to progress in initiatives with pharmaceutical companies and life insurance companies that utilize data, initiatives for payers/individuals are also gaining momentum, including collaboration with local governments and the expansion of functions for individuals such as "Pep Up Sleep."

• The social implementation of data is progressing thanks to the volume of data accumulated to date and our user foundation. Furthermore, as the social implementation of data progresses, it will lead to further expansion of data volume and user foundation. We

are confident that this virtuous cycle of expanding data volume and user foundation, coupled with the social implementation of data, 4

will establish a sustainable competitive advantage that is unique to our company.

FY2025 Q1: Summary of Consolidated Performance

Both revenue and profit grew steadily.

(Unit: Million JPY)FY2024 Q1 FY2025 Q1 Y-o-Y

8,096 10,725 +32%

1,042

(13%)

Profit before taxes

(Rate)

1,025

(13%)

727

(9%)

1,552

(15%)

1,441

(13%)

966

(9%)

+49%

+41%

+33%

693 966 +39%

34 - -

1,649

(20%)

2,267

(21%)

+38%

5

Note: IFRS-based

EBITDA: Operating profit + Depreciation and amortization costs ± Other profits and/or losses, EBITDA margin: EBITDA/Revenue